These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 7545698)

  • 1. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia.
    Baxter RC; Holman SR; Corbould A; Stranks S; Ho PJ; Braund W
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2700-8. PubMed ID: 7545698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of growth hormone treatment on the insulin-like growth factor axis in a child with nonislet cell tumor hypoglycemia.
    Katz LE; Liu F; Baker B; Agus MS; Nunn SE; Hintz RL; Cohen P
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1141-6. PubMed ID: 8772589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors.
    Baxter RC; Daughaday WH
    J Clin Endocrinol Metab; 1991 Oct; 73(4):696-702. PubMed ID: 1716259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.
    Zapf J; Schmid C; Guler HP; Waldvogel M; Hauri C; Futo E; Hossenlopp P; Binoux M; Froesch ER
    J Clin Invest; 1990 Sep; 86(3):952-61. PubMed ID: 1697608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia.
    Baxter RC
    Horm Res; 1996; 46(4-5):195-201. PubMed ID: 8950621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia.
    Bourcigaux N; Arnault-Ouary G; Christol R; Périn L; Charbonnel B; Le Bouc Y
    Clin Ther; 2005 Feb; 27(2):246-51. PubMed ID: 15811488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
    Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs.
    Lee CY; Rechler MM
    Endocrinology; 1995 Nov; 136(11):4982-9. PubMed ID: 7588232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme.
    Ono T; Kanzaki S; Seino Y; Baylink DJ; Mohan S
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2111-6. PubMed ID: 8964836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH.
    Zhou X; Loke KY; Pillai CC; How HK; Yap HK; Lee KO
    Eur J Endocrinol; 2001 Mar; 144(3):237-43. PubMed ID: 11248742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that human bone cells in culture secrete insulin-like growth factor (IGF)-II and IGF binding protein-3 but not acid-labile subunit both under basal and regulated conditions.
    Kanzaki S; Baxter RC; Knutsen R; Baylink DJ; Mohan S
    J Bone Miner Res; 1995 Jun; 10(6):854-8. PubMed ID: 7572308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
    Gargosky SE; Tapanainen P; Rosenfeld RG
    Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans.
    Olivecrona H; Hilding A; Ekström C; Barle H; Nyberg B; Möller C; Delhanty PJ; Baxter RC; Angelin B; Ekström TJ; Tally M
    J Clin Endocrinol Metab; 1999 Feb; 84(2):553-60. PubMed ID: 10022415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum levels of acid-labile subunit in patients with anorexia nervosa.
    Fukuda I; Hotta M; Hizuka N; Takano K; Ishikawa Y; Asakawa-Yasumoto K; Tagami E; Demura H
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2034-6. PubMed ID: 10372706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.
    Gargosky SE; Wilson KF; Fielder PJ; Vaccarello MA; Guevara-Aguirre J; Diamond FB; Baxter RC; Rosenbloom AL; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1683-9. PubMed ID: 7505289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?
    Zapf J; Futo E; Peter M; Froesch ER
    J Clin Invest; 1992 Dec; 90(6):2574-84. PubMed ID: 1281841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A major portion of the 150-kilodalton insulin-like growth factor-binding protein (IGFBP) complex in adult rat serum contains unoccupied, proteolytically nicked IGFBP-3 that binds IGF-II preferentially.
    Lee CY; Rechler MM
    Endocrinology; 1995 Feb; 136(2):668-78. PubMed ID: 7530649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.